
Avidity Biosciences Inc
NASDAQ:RNA

Intrinsic Value
The intrinsic value of one
RNA
stock under the Base Case scenario is
22.03
USD.
Compared to the current market price of 29.03 USD,
Avidity Biosciences Inc
is
Overvalued by 24%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Avidity Biosciences Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Avidity Biosciences Inc
Balance Sheet Decomposition
Avidity Biosciences Inc
Current Assets | 1.4B |
Cash & Short-Term Investments | 1.4B |
Receivables | 36.6m |
Other Current Assets | 18.5m |
Non-Current Assets | 24.1m |
PP&E | 20.6m |
Other Non-Current Assets | 3.5m |
Free Cash Flow Analysis
Avidity Biosciences Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Avidity Biosciences Inc
Revenue
|
8.9m
USD
|
Operating Expenses
|
-442.2m
USD
|
Operating Income
|
-433.3m
USD
|
Other Expenses
|
64m
USD
|
Net Income
|
-369.2m
USD
|
RNA Profitability Score
Profitability Due Diligence
Avidity Biosciences Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.

Score
Avidity Biosciences Inc's profitability score is 39/100. The higher the profitability score, the more profitable the company is.
RNA Solvency Score
Solvency Due Diligence
Avidity Biosciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Score
Avidity Biosciences Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RNA Price Targets Summary
Avidity Biosciences Inc
According to Wall Street analysts, the average 1-year price target for
RNA
is 68.2 USD
with a low forecast of 50.5 USD and a high forecast of 100.8 USD.
Dividends
Current shareholder yield for RNA is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
RNA
stock under the Base Case scenario is
22.03
USD.
Compared to the current market price of 29.03 USD,
Avidity Biosciences Inc
is
Overvalued by 24%.